Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Genetic S P A has 2 pending office actions currently active in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This distribution shows that each pending matter is being handled by a different individual in a different technical group, requiring a specialized approach for each filing.
The busiest examiner for the portfolio is SZNAIDMAN, MARCOS L, who is handling 1 pending office action. This workload is distributed such that no single individual manages all 2 pending office actions. This means that no single examiner has a majority influence over the company's current pending matters.
With 2 distinct art units involved, the company must navigate the specific examination guidelines of different technical divisions. The presence of 2 distinct examiners, including SZNAIDMAN, MARCOS L, suggests that the prosecution outcomes will depend on the individual interpretations of these separate officials.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| PIHONAK, SARAH | 1 | 61.4% | +42.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | SZNAIDMAN, MARCOS L | — |
| 18579645 | PROCESS FOR THE PREPARATION OF BUDESONIDE 21-PHOSPHATE | PIHONAK, SARAH | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | SZNAIDMAN, MARCOS L | 1628 | §102§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18579645 | PROCESS FOR THE PREPARATION OF BUDESONIDE 21-PHOSPHATE | PIHONAK, SARAH | 1627 | §103 | Non-Final OA | — | Pending | Jan 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenetic S P A has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Marcos L Sznaidman has the most, with 1 of Genetic S P A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
